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BACKGROUND: Compared with vitamin K antagonists, direct-acting oral anticoagulants (DOACs) have
ﬁxed dosing, limited drug interactions, and do not require therapeutic drug level monitoring. Dose ad-
justments are recommended for moderate renal dysfunction, low body weight, and select drug
interactions.
OBJECTIVES: The aim of our study is to determine if DOAC dose reductions were appropriate based on the
manufacturer labeling recommendations for each agent. We also followed patients’ treatment outcomes.
METHODS: We retrospectively reviewed patients administered a DOAC at a reduced dose between January
2011 and August 2014. The primary outcome was adherence to current manufacturer dose recommenda-
tions. The secondary outcome measures were the incidence of thromboembolic events or any bleeding
episodes, regardless of severity, while on therapy.
RESULTS: Of 224 patients included in the analysis, 43.3% of patients ﬁt criteria for a dose adjustment
according to manufacturer recommendations. Only 3 of 28 (10.7%) patients treated with apixaban met 2 out
of 3 clinical criteria required for a dose reduction per manufacturer recommendations. Only 54.7% of
rivaroxaban-treated patients and 32.2% of dabigatran-treated patients had renal insufﬁciency requiring a
dose reduction. Half of our patient population received aspirin therapy, with 6.3% of patients on triple
antithrombotic therapy (dual antiplatelet agents plus an anticoagulant). A past medical history signiﬁcant
for bleeding was prevalent in patients treated with a reduced-dose DOAC (32.1%, 20.4%, and 25.4% of
patients in the apixaban-, rivaroxaban-, and dabigatran-treated groups, respectively). Thromboembolic
events occurred in 10.7%, 3.6%, and 5.1% of patients in the apixaban, rivaroxaban, and dabigatran groups,
respectively. Frequency of bleeding complications, regardless of severity, was 17.9%, 18.2%, and 23.7% of
patients in the apixaban, rivaroxaban, and dabigatran groups, respectively.
CONCLUSION: We found that dose-adjusted DOAC therapy was often prescribed in a dose that was lower
than package insert recommendations.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
129, 1198-1204
KEYWORDS: Anticoagulation; Atrial ﬁbrillation; Dose reduction; Drug interactions; Renal dysfunction; Venousr
t
e
p
i
6
4
0thromboembolisme was no external support for this study.
erest: All authors of this article have no conﬂicts to
ll authors participated in the data collection, analysis,
paration.
rints should be addressed to Samuel Z. Goldhaber, MD,
vision, Brigham and Women’s Hospital, 75 Francis
02115.
: sgoldhaber@partners.org
The Authors. Published by Elsevier Inc. This is an open acc
.0/).
.1016/j.amjmed.2016.05.041Compared with vitamin K antagonists, direct-acting oral
anticoagulants (DOACs) have more predictable pharmaco-
dynamics, fewer drug interactions, and do not require lab-
oratory coagulation monitoring.1 While current guidelines
do not recommend a preference for one DOAC over
another, as a group they have similar efﬁcacy and an
improved safety proﬁle, with less intracranial bleeding and
hemorrhagic stroke in atrial ﬁbrillation and fewer majoress article under the CC BY-NC-ND license (http://creativecommons.org/
Barra et al Direct Oral Anticoagulant Dose Reduction 1199bleeding episodes in the treatment of acute venous throm-
boembolism when compared to vitamin K antagonists.2-5
The 2016 CHEST Guidelines recommend DOACs rather
than warfarin to treat acute venous thromboembolism.6
When treating patients with DOACs, dose reductions are
recommended for patients with moderate renal impairment,CLINICAL SIGNIFICANCE
 Direct-acting oral anticoagulants are
commonly prescribed in a reduced dose
that is outside the package insert
recommendations.
 Mild to moderate renal dysfunction, a
past medical history of bleeding events,
and concomitant use of medications that
increased bleeding risk were frequent in
patients prescribed a reduced direct-
acting oral anticoagulant dose.
 Our ﬁndings highlight differenceslow body weight, and concomitant
medications that may impact
metabolism through the P-glyco-
protein transport system or hepatic
cytochrome p-450.7-9
The objective of our study was
to determine whether DOAC dose
reductions for inpatients at our
institution matched US Food and
Drug Administration labeling rec-
ommendations for each agent. We
also aimed to evaluate the pre-
scribing practices of physicians
utilizing DOACs at reduced doses
and the outcomes of patients
treated.between anticoagulant dosing derived
from randomized clinical trials vs dosing
based upon individual assessment of
patients’ risks for thrombosis and
bleeding. The optimum choice remains
uncertain.METHODS
We performed a retrospective re-
view, using the hospital’s elec-
tronic health record to identify
consecutive hospitalized patients
administered a DOAC between
January 2011 and August 2014 for
treatment of venous thromboembolism, secondary preven-
tion of recurrent venous thromboembolism, or stroke pre-
vention in nonvalvular atrial ﬁbrillation. Edoxaban use was
not evaluated because it was not approved by the Food and
Drug Administration until after the study period
commenced. We included patients who were 18 years old
and were administered a reduced-dose DOAC. We excluded
patients if anticoagulation was prescribed for venous
thromboembolism prophylaxis or if a DOAC was prescribed
for an off-label indication.
Our primary outcome evaluated whether the DOAC dose
was adjusted in accordance with current package insert la-
beling. Our secondary outcomes were the incidence of
thromboembolic and bleeding events while on therapy. We
completed a 1-year follow-up on study patients by identi-
fying endpoints after hospitalization through our health
systems’ computerized longitudinal medical record. Within
our integrated health care system, any patient encounter
across 6 hospitals, 17 ambulatory clinics, and numerous
private practices is recorded in the longitudinal medical
record. We captured all subsequent hospitalizations and
discharge summaries, ofﬁce visits and clinicians’ notes,
laboratory tests, medical treatments, and diagnostic pro-
cedures, regardless of the facility or ofﬁce location.
Clinically relevant drug interactions were determined
according to Heidbuchel et al’s analysis on the effects ofDOAC plasma levels with concomitant administration of
interacting medications.10 Baseline creatinine clearance was
calculated utilizing the Cockcroft-Gault equation. Actual
body weight was utilized if a patient weighed less than his
or her estimated ideal body weight. In patients whose actual
body weight was >130% of ideal body weight, the idealbody weight was adjusted utilizing
the adjusted body weight formula
(Adjusted body weight ¼ Ideal
body weight þ 0.4[actual body
weight  ideal body weight]).
Body mass index was calculated
using the formula body mass
index ¼ weight (kg)/height (m)2.RESULTS
We identiﬁed 224 patients who
received a reduced DOAC dose
(Figure 1), representing an
estimated 13.3% (224/1680) of
patients prescribed a DOAC at
our institution during the study
period. The majority of patients
(137; 61.1%) were treated with
rivaroxaban, followed by dabi-
gatran (59; 26.3%) and apixaban
(28; 12.5%) (Table 1). The mean
age was 77.7 years, with 47.3%
of patients 80 years or older.
Most patients were prescribedanticoagulant therapy for atrial ﬁbrillation or atrial ﬂutter
(82.1%, 88.3%, 98.3% of patients in the apixaban,
rivaroxaban, and dabigatran groups, respectively).
Creatinine clearance was widely distributed, with pa-
tients most commonly falling between 30 and 49 mL/min
(50.0%, 48.2%, and 44.1% of patients in the apixaban,
rivaroxaban, and dabigatran groups, respectively; Table 1,
Figure 2). The mean body mass index across patient
groups was 29.3 kg/m2. Approximately 38% of patients
were obese, with a body mass index 30 kg/m2.Renal Dysfunction and Labeling
Recommendations
Of 224 patients, 97 (43.3%) were dosed as recommended by
the manufacturer labeling (54.7% in rivaroxaban group,
32.2% in dabigatran group, and 10.7% in apixaban group).
In patients anticoagulated with apixaban for stroke pre-
vention in atrial ﬁbrillation, 2 of 3 clinical characteristics are
required for a dose reduction to be warranted according to
package insert labeling (actual body weight 60 kg, age 80
years, and serum creatinine 1.5 mg/dL). Three of 24
(12.5%) patients treated with apixaban for atrial ﬁbrillation in
our study met these criteria. Eight of 24 patients (33.3%) met
none of these criteria, while 54.2% (13/24) met only 1 of the
3 criteria. Of the 24 patients, 10 patients had an age 80
Patients 
Evaluated for 
Inclusion
(n = 1680)
Patients 
Included in 
Final Analysis 
(n = 224)
Apixaban              
(n = 28)
2.5 mg PO daily 
(n = 1)
2.5 mg PO 
twice daily                     
(n = 27)
Rivaroxaban        
(n = 137)
10 mg PO daily   
(n = 14)
15 mg PO daily   
(n = 123)
Dabigatran         
(n = 59)
75 mg PO  
twice daily                     
(n = 59)
Figure 1 Direct oral anticoagulant dosing. PO ¼ by mouth.
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patients presented with a serum creatinine 1.5 mg/dL. Four
patients anticoagulated for the treatment of venous throm-
boembolism were dose-reduced despite the absence of dose-
adjustment recommendations in this patient population.
In the rivaroxaban-treated atrial ﬁbrillation patients, 75
(62.0%) met the dose reduction criteria based on a calcu-
lated creatinine clearance of 15-50 mL/min. While 3 patients
met the creatinine clearance value for dose reduction, they
received 10 mg daily rather than the recommended 15 mg
daily. In this group, 45 patients (37.2%) did not have a
creatinine clearance 50 mL/min to warrant a dose adjust-
ment per package insert recommendations. Of these 45 pa-
tients, 60% (27/45) had a calculated creatinine clearance of
50-60 mL/min. Two patients with atrial ﬁbrillation were
treated with reduced-dose rivaroxaban (10 mg daily),
despite having a calculated creatinine clearance <15 mL/
min, a contraindication to treatment.
In the rivaroxaban-treated patients with venous throm-
boembolism, all 12 patients were dose-reduced despite a
lack of labeling recommendations for dose reduction beyond
the contraindication of use in patients with a creatinine
clearance <30 mL/min. The average creatinine clearance in
these patients was 47.0 mL/min; range 21.4-88.6 mL/min.
All patients treated with dabigatran had atrial ﬁbrillation
at baseline, with one patient having concurrent venous
thromboembolism. In the dabigatran-treated patients, 19
(32.2%) met dose-reduction criteria of an estimated creati-
nine clearance 30 mL/min. For the 40 patients with a
creatinine clearance >30 mL/min, 82.5% had moderate
renal dysfunction (creatinine clearance 30-60 mL/min).Concomitant Interacting Medications
Concomitant medication use that could impact DOAC
treatment was prominent in our patient population.
Approximately half of all patients were also receivingaspirin therapy, encompassing 46.4%, 55.5%, and 50.8% of
patients in the apixaban, rivaroxaban, and dabigatran
groups, respectively. Triple antithrombotic therapyedual
antiplatelet therapy plus anticoagulationewas utilized in
8.8% and 1.7% of rivaroxaban and dabigatran patients,
respectively.
In patients treated with apixaban, 4 of 28 (14.2%) pa-
tients were on concomitant diltiazem, where a dose reduc-
tion should be considered if 2 or more risk factors (age 75
years, weight 60 kg, renal dysfunction, antiplatelet drugs,
nonsteroidal anti-inﬂammatory agents, steroid therapy, his-
tory of gastrointestinal bleeding, recent surgery on a critical
organ, or thrombocytopenia) are present.10 Of these 4 pa-
tients, 3 patients had one or more additional risk factors for
bleeding.
Of the rivaroxaban-treated patients, 6 (4.4%) had
potentially clinically signiﬁcant drug interactions, with 3
(2.2%) patients receiving concomitant tacrolimus and 3
(2.2%) receiving cyclosporine. Of these patients, 2 patients
had renal dysfunction with an estimated creatinine clearance
45-50 mL/min.
For patients treated with dabigatran, 3 (5.1%) patients
were on concomitant amiodarone, of which 2 patients had a
baseline creatinine clearance 30 mL/min.Past Medical History Signiﬁcant for Bleeding
A history of bleeding was a common characteristic in
patients treated with a reduced DOAC dose (32.1%,
20.4%, and 25.4% of patients in the apixaban, rivaroxaban,
and dabigatran treated groups, respectively). The most
common type of prior bleeding event was gastrointestinal
(Table 1).
For the 9 patients with bleeding episodes prior to the start
of dose-reduced apixaban, the average calculated creatinine
clearance was 52.8 mL/min (range 24.9-93.8 mL/min). Four
patients were 80 years of age or older (of whom 3 patients
Table 1 Baseline Characteristics According to Treatment Group
Characteristic Apixaban (n ¼ 28) Rivaroxaban (n ¼ 137) Dabigatran (n ¼ 59)
Age e y 77  10.1* 76  11* 81  8*
<65 y e n (%) 4 (14.3) 19 (13.8) 2 (3.4)
65-80 y e n (%) 11 (39.3) 52 (38.0) 20 (33.9)
80 y e n (%) 13 (46.4) 66 (48.2) 37 (62.7)
Male sex e n (%) 13 (46.4) 74 (54.0) 31 (52.5)
Creatinine clearance e n (%)
<15 mL/min 0 (0) 2 (1.5) 0 (0)
15-29 mL/min 3 (10.7) 17 (12.4) 17 (28.8)
30-49 mL/min 14 (50.0) 66 (48.2) 26 (44.1)
50-79 mL/min 8 (28.6) 43 (31.4) 12 (20.3)
80 mL/min 3 (10.7) 9 (6.5) 4 (6.8)
Weight e kg 75.8  13.9* 82.6  20.9* 83.4  23.0*
60 kg e n (%) 4 (14.3) 17 (12.4) 7 (11.9)
Body mass index e kg/m2 27.9  5.0* 29.3  6.6* 29.4  7.3*
<30 kg/m2 e n (%) 15 (53.6) 85 (32.0) 38 (64.4)
30 kg/m2 e n (%) 13 (46.4) 52 (38.0) 21 (35.6)
Total daily dose e mg (range) 4.9 (2.5-5) 14.5 (10-15) 150 (150)
Initial Diagnosis e n (%)
Atrial ﬁbrillation/atrial ﬂutter 23 (82.1) 121 (88.3) 58 (98.3)
Venous thromboembolism treatment or prophylaxis 4 (14.3) 12 (8.8) 0 (0)
Atrial ﬁbrillation and venous thromboembolism 1 (3.6) 4 (2.9) 1 (1.7)
Cancer e n (%) 7 (25.0) 31 (22.6) 15 (25.4)
Prior bleeding episode† e n (%) 9 (32.1) 28 (20.4) 15 (25.4)
Total bleeding episodes e n 12 26 17
Gastrointestinal 3 (25.0) 14 (53.8) 6 (35.3)
Rectal 2 (16.7) 3 (11.5) 2 (11.8)
Hemoptysis 1 (8.3) 1 (3.8) 2 (11.8)
Hematuria 2 (16.7) 1 (3.8) 1 (5.9)
Epistaxis 0 (0) 3 (11.5) 1 (5.9)
Subarachnoid hemorrhage 2 (16.7) 0 (0) 2 (11.8)
Subdural hematoma 0 (0) 1 (3.8) 2 (11.8)
Hemorrhagic stroke 1 (8.3) 0 (0) 0 (0)
Other 1 (8.3) 3 (11.5) 1 (5.9)
Medication use at baseline
Aspirin 12 (46.4) 76 (55.5) 30 (50.8)
P2Y12 inhibitor 2 (7.1) 12 (8.8) 2 (3.4)
Amiodarone 0 (0) 0 (0) 3 (5.1)
Diltiazem 4 (14.3) 0 (0) 0 (0)
Cyclosporine/tacrolimus 0 (0) 6 (4.4) 0 (0)
* Values signify mean  standard deviation.
†Some patients had more than 1 bleeding event.
Barra et al Direct Oral Anticoagulant Dose Reduction 1201had a creatinine clearance 20-50 mL/min and 1 patient a
creatinine clearance between 50 and 80 mL/min). Of 28
patients with a prior bleeding history who were treated with
rivaroxaban, the average estimated creatinine clearance was
49.0 mL/min (range 14.2-111.4 mL/min). In the 15 patients
who had a bleed prior to the start of dabigatran, the average
calculated creatinine clearance was 36.5 mL/min (range
19.5-57.2 mL/min).Efﬁcacy and Safety Outcomes
Thromboembolic events occurred in 4.9% of our patient
population (Table 2). For patients who were
anticoagulated for stroke prevention in atrial ﬁbrillation,there were 10 thromboembolic events. Two of 23
patients in the apixaban group (8.6%) had
thromboembolic events; one patient had a myocardial
infarction, and a second patient was diagnosed with a
stroke. In rivaroxaban-treated patients with atrial ﬁbrilla-
tion, thromboembolic events occurred in 4.1% (5/121) of
patients, with 2.5% (3/121) diagnosed with a stroke/tran-
sient ischemic attack, 0.8% (1/121) recurrent venous
thromboembolism, and 0.8% (1/121) myocardial infarc-
tion. Of patients with atrial ﬁbrillation who were treated
with dabigatran, there were 3 thromboembolic events in 59
patients (5.1%), with one occurrence of each of the
following events: venous thromboembolism, stroke/tran-
sient ischemic attack, or myocardial infarction. There was
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Figure 2 Renal function in patients on reduced-dose anticoagulation.
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anticoagulated for the treatment of venous thromboembo-
lism/prophylaxis of recurrent venous thromboembolism.
This patient had recurrent venous thromboembolism while
on apixaban therapy. There were no thromboembolic
events in atrial ﬁbrillation patients who also were being
treated for venous thromboembolism.
Forty-four (19.6%) patients had a bleeding event while on
reduced-dose DOAC therapy. Episodes of bleeding were
more common in the dabigatran-treated patients, with 23.7%
(14/59) of patients experiencing a bleed during
therapy, followed by patients treated with rivaroxabanTable 2 Clinical Outcome Measures
Outcome Apixaban (n ¼ 28)
Thromboembolic event e n (%)
Venous thromboembolism 1 (3.6)
Stroke/transient ischemic attack 1 (3.6)
Myocardial infarction 1 (3.6)
Any bleeding episode* e n (%) 5 (17.9)
Gastrointestinal 4 (14.3)
Rectal 0 (0)
Hemoptysis 1 (3.6)
Hematuria 0 (0)
Epistaxis 0 (0)
Subarachnoid hemorrhage 0 (0)
Subdural hematoma 0 (0)
Brainstem/intraventricular hemorrhage 0 (0)
Unknown source 0 (0)
Other 0 (0)
*Some patients had more than one bleeding event.(18.2%, 25/137) and apixaban (17.9%, 5/28). Gastrointestinal
bleeding was the most common type of bleed in patients,
occurring in 14.3%, 7.35%, and 11.9% in the apixaban,
rivaroxaban, and dabigatran group, respectively (Table 2).
Twenty-nine of these patients were on concurrent antiplate-
let therapy, with 22 (50%) on aspirin monotherapy, 1 (2.3%)
on clopidogrel monotherapy, and 6 (13.6%) on dual anti-
platelet therapy (Table 3). Renal function averaged a
creatinine clearance of 39.2 mL/min (30.1-51.2 mL/min) in
apixaban-treated patients, 42.5 mL/min (14.2-108.3 mL/
min) in the rivaroxaban group, and 40.5 mL/min (21.2-91.3
mL/min) in the dabigatran group.Rivaroxaban (n ¼ 137) Dabigatran (n ¼ 59)
1 (0.7) 1 (1.7)
3 (2.2) 1 (1.7)
1 (0.7) 1 (1.7)
25 (18.2) 14 (23.7)
10 (7.3) 7 (11.9)
1 (0.7) 2 (3.4)
1 (0.7) 0 (0)
3 (2.2) 1 (1.7)
7 (5.1) 1 (1.7)
0 (0) 1 (1.7)
1 (0.7) 1 (1.7)
1 (0.7) 0 (0)
3 (2.2) 0 (0)
3 (2.2) 2 (3.4)
Table 3 Characteristics of Patients with a Bleeding Event on Reduced-Dose Anticoagulation
Characteristic e n (%) Apixaban (n ¼ 5) Rivaroxaban (n ¼ 25) Dabigatran (n ¼ 14)
Total bleeding events e n* 5 30 15
Age e y
<65 y 0 (0) 4 (16.0) 0 (0)
65-80 y 3 (60.0) 10 (40.0) 3 (21.4)
80 y 2 (40.0) 11 (44.0) 11 (78.6)
Weight 60 kg 1 (20.0) 4 (16.0) 1 (7.1)
Creatinine clearance, mL/min† 39.2 (30.1-51.2) 42.5 (14.2-108.3) 40.5 (21.2-91.3)
Prior bleeding episode 0 (0) 5 (20.0) 5 (35.7)
Medication use at baseline
Aspirin 3 (60.0) 17 (68.0) 8 (57.1)
Clopidogrel 1 (20.0) 4 (16.0) 2 (14.3)
Cyclosporine 0 (0) 1 (4.0) 0 (0)
*Some patients had more than one bleeding event.
†Data presented as mean (range).
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We found that in patients prescribed reduced-dose antico-
agulants, the dose reductions were often not based on Food
and Drug Administration-approved prescribing recommen-
dations. Mild to moderate renal dysfunction, a past medical
history of bleeding events, and concomitant use of medi-
cations that increased bleeding risk were frequent in patients
prescribed a reduced DOAC dose (Figure 3). After
excluding patients with clinical risk factors that may
contribute to an increased bleeding risk, 33 patients
(14.7%) had no apparent clinical rationale that we could
deduce from chart review to warrant a dose reduction.
While dose-adjustment recommendations exist for pa-
tients with renal dysfunction, clinical trials for DOACs
typically excluded patients with severe renal dysfunction
(creatinine clearance <30 mL/min).11-17 Current DOACFigure 3 Baseline characteristics at therapy
initiation.dosing recommendations for renal dysfunction are based
upon either the results of randomized clinical trials or upon
pharmacodynamic and pharmacokinetic models. The half-
life of the DOAC may be increased by as much as 100%,
depending on the agent’s renal clearance.3,10 Postmarketing
surveillance of nonvalvular atrial ﬁbrillation patients treated
with dabigatran found that 16% of the study population
received dose-adjusted dabigatran. Of these patients, only
33% had a diagnosis of chronic kidney disease (20% were
coded explicitly for severe renal impairment). While this
study concluded that dabigatran use was associated with a
reduced risk of ischemic stroke, intracranial hemorrhage,
and death with an increased risk of gastrointestinal bleeding,
subgroup analysis found that patients treated with a dose-
adjusted dabigatran did not have distinguishable differ-
ences in outcomes compared to warfarin, with the critically
important exception of a lower risk of intracranial
hemorrhage.18
We found that a past medical history for bleeding inﬂu-
enced DOAC reduced-dose prescribing. Despite dose re-
ductions, bleeding events still occurred in approximately
20% of patients. Bleeding event rates were slightly higher
than observed in randomized clinical trials of DOACs.
In patients anticoagulated for stroke prevention in atrial
ﬁbrillation, dose adjustments are advised in patients with
high-risk clinical features, such as renal dysfunction, older
age, or extremes of body weight depending on which
DOAC is prescribed. In contrast, there is limited guidance
for patients who are anticoagulated with DOACs for the
treatment of venous thromboembolism with these clinical
features. Current manufacturer recommendations do not
recommend the use of select DOACs in severe renal
dysfunction (creatinine clearance <25 mL/min for apix-
aban or a creatinine clearance <30 mL/min for rivarox-
aban and dabigatran) for the treatment of venous
thromboembolism. For patients who do not meet this
contraindication, manufacturers do not suggest a dose
1204 The American Journal of Medicine, Vol 129, No 11, November 2016adjustment is required for the treatment of venous
thromboembolism, regardless of the presence of comorbid
conditions. There is limited evidence to guide clinicians in
patients with high-risk clinical features.7-9 Recently
approved edoxaban is the ﬁrst DOAC to address the
presence of comorbid conditions and to recommend dose
reductions for patients with venous thromboembolism who
have renal dysfunction, low body weight, or select drug
interactions.19 The critically important question is whether
the labeled dose-reduction parameters in package inserts
for DOACs constitute best practices or whether clinical
judgment should override these rigid guidelines. It appears
that in our hospitalized population of elderly patients with
renal dysfunction and multiple medical comorbidities,
many would not have been eligible to participate in the
clinical trials that led to the formulation of dose reduction
guidelines.
There are data from doseeresponse curves of stroke
prevention in atrial ﬁbrillation trials with dabigatran and
edoxaban indicating that there is a steep doseeresponse
curve for bleeding complications, but a shallow dos-
eeresponse curve for thrombotic events.20,21 These data
raise the possibility that rigid adherence to package insert
guidelines should be modiﬁed according to individualized
patient assessment for susceptibility to bleeding.
Our review has several limitations. We employed a
retrospective chart review design and assumed that patients
were taking their medication as prescribed. Additionally, we
did not query the prescriber to identify their methodology or
intent behind their initiation of a reduced dose. Our review
does have strengths. We believe it provides a “real world”
picture of anticoagulant prescribing practices, offering
insight into common characteristics of patients who are
treated with a DOAC at a reduced dose.
Our study conﬁrms that DOACs in practice are frequently
prescribed at a lower-than-recommended dose. Whether this
common clinical practice is a “best practice” based upon in-
dividual assessment of patients’ risks for bleeding remains
uncertain. Our ﬁndings highlight differences between the
population-wide recommendations derived from randomized
clinical trials vs the concept of personalized medicine. The
clinician’s challenge is to combine the “art” of medicine with
the “science” of medicine.CONCLUSIONS
Dose reductions were often made for DOAC use in the
inpatient setting despite package labeling recommendations
for higher doses. Multiple patient comorbidities that would
have excluded many of these patients from participating in
randomized clinical trials likely played a role in prescriber
decision-making and cautious reduced dosing of DOACs.
Further evaluation of these patient populations in real-world
settings will assist clinicians in determining the best practice
for those patients who do not meet the strict eligibility
proﬁle of the large clinical trials.References
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